BI 705564

Drug Profile

BI 705564

Alternative Names: BI705564

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 01 Nov 2017 Boehringer Ingelheim plans a phase I trial in healthy volunteers in Germany in November 2017 (NCT03325712)
  • 27 Apr 2017 Phase-I clinical trials in Undefined indication (In volunteers) in Germany (PO, Liquid) (NCT03123185)
  • 27 Apr 2017 Phase-I clinical trials in Undefined indication (In volunteers) in Germany (PO, Tablet) (NCT03123185)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top